Dwight Egan 의 보수는 Co-Diagnostics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$39m
Dec 31 2023	US$1m	US$375k	-US$35m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$2m	US$366k	-US$14m
Sep 30 2022	n/a	n/a	US$15m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	US$40m
Dec 31 2021	US$2m	US$350k	US$37m
Sep 30 2021	n/a	n/a	US$42m
Jun 30 2021	n/a	n/a	US$46m
Mar 31 2021	n/a	n/a	US$51m
Dec 31 2020	US$1m	US$309k	US$42m
Sep 30 2020	n/a	n/a	US$28m
Jun 30 2020	n/a	n/a	US$10m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$460k	US$275k	-US$6m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$474k	US$275k	-US$6m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$210k	US$195k	-US$7m

보상 대 시장: Dwight 의 총 보상 ($USD 1.26M )은 US 시장( $USD 683.56K ).

보상과 수익: Dwight 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dwight Egan (71 yo)

11.4yrs

테뉴어

US$1,261,300

보상

Mr. Dwight H. Egan serves as the Chairman & Chief Executive Officer and was President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment bus...

리더십 팀

이름	위치	테뉴어	보상	소유권
Dwight Egan	Chairman & CEO	no data	US$1.26m	1.15% $ 451.7k
Brian Brown	CFO & Company Secretary	3.6yrs	US$1.04m	0.91% $ 357.5k
Richard Abbott	President	less than a year	데이터 없음	1.85% $ 726.7k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	11.4yrs	US$237.50k	데이터 없음
David Nielsen	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Dan Bohrer	Vice President of Finance & Accounting	no data	데이터 없음	데이터 없음
Christopher Thurston	Chief Technology Officer	less than a year	데이터 없음	데이터 없음
Andrew Benson	Head of Investor Relations	no data	데이터 없음	데이터 없음
Mayuranki Almaula	Senior Vice President of Overseas Operations & Strategic Alliances	no data	데이터 없음	데이터 없음
Cameron Gundry	Head of Commercialization LATAM/EUR	no data	데이터 없음	데이터 없음
Ivory Chang	Chief Regulatory Affairs Officer	1.1yrs	데이터 없음	데이터 없음
Seth Egan	Chief Commercialization Officer	less than a year	데이터 없음	데이터 없음

0.5yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: CODX 의 관리팀은 경험 (평균 재직 기간 0.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dwight Egan	Chairman & CEO	11.4yrs	US$1.26m	1.15% $ 451.7k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	2.5yrs	US$237.50k	데이터 없음
Richard Serbin	Independent Director	7.3yrs	US$298.00k	0.37% $ 144.5k
Carl Wittwer	Chairman of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
James Nelson	Independent Director	5.1yrs	US$298.00k	0.36% $ 141.5k
Noriko Kusukawa	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Edward Murphy	Independent Director	5.3yrs	US$298.00k	0.40% $ 156.8k
Eugene Durenard	Independent Director	5.3yrs	US$298.00k	0.36% $ 141.5k
Karen Carroll	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Anne Wyllie	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: CODX 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

Co-Diagnostics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Chairman exercised options and sold US$58k worth of stock

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Chairman exercised options and sold US$111k worth of stock

Recent updates

Consensus revenue estimates increase by 143%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Chairman exercised options and sold US$58k worth of stock

Consensus revenue estimates increase by 474%

Price target increased by 50% to US$3.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Consensus revenue estimates fall by 43%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Consensus revenue estimates fall by 83%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Chairman exercised options and sold US$111k worth of stock

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Co-Diagnostics: Hold Thesis Remains Well Intact

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Price target decreased to US$15.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Co-Diagnostics spikes on shipments of monkeypox test

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Now 24% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Chairman exercised options and sold US$59k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to US$19.33

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Co-Diagnostics: Where's Eikon?

High number of new and inexperienced directors

Consensus EPS estimates increase by 36%

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week